<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33434914</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1665-1146</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Boletin medico del Hospital Infantil de Mexico</Title><ISOAbbreviation>Bol Med Hosp Infant Mex</ISOAbbreviation></Journal><ArticleTitle>[Acute pancreatitis in children with hemato-oncological diseases: clinical aspects and treatment].</ArticleTitle><Pagination><StartPage>95</StartPage><MedlinePgn>95-101Pancreatitis aguda</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/BMHIM.20000110</ELocationID><Abstract><AbstractText>La pancreatitis aguda es una enfermedad inflamatoria del p&#xe1;ncreas. Se observa con mayor frecuencia en ni&#xf1;os bajo tratamiento por alguna enfermedad hematooncol&#xf3;gica y se asocia principalmente con la administraci&#xf3;n de L-asparaginasa. Identificar esta complicaci&#xf3;n de forma temprana y establecer un plan terap&#xe9;utico adecuado puede mejorar el pron&#xf3;stico y reducir el riesgo de otras complicaciones. En este trabajo se realiz&#xf3; una revisi&#xf3;n cr&#xed;tica de la literatura actual, con especial &#xe9;nfasis en los aspectos cl&#xed;nicos, el diagn&#xf3;stico y el tratamiento de la pancreatitis aguda en ni&#xf1;os con c&#xe1;ncer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Aguilar</LastName><ForeName>L&#xe9;nica A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Servicio de Hematolog&#xed;a Pedi&#xe1;trica, Centro M&#xe9;dico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;a-V&#xe9;lez</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Gastroenterolog&#xed;a y Nutrici&#xf3;n, Instituto Nacional de Pediatr&#xed;a; Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Pancreatitis aguda en ni&#xf1;os con enfermedades hematooncol&#xf3;gicas: aspectos cl&#xed;nicos y tratamiento.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Bol Med Hosp Infant Mex</MedlineTA><NlmUniqueID>0414106</NlmUniqueID><ISSNLinking>0539-6115</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pancreatitis aguda</Keyword><Keyword MajorTopicYN="N">Leucemia linfobl&#xe1;stica aguda</Keyword><Keyword MajorTopicYN="N">L-asparaginasa</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33434914</ArticleId><ArticleId IdType="doi">10.24875/BMHIM.20000110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30250314</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><Issue>4</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Importancia del "diagn&#xf3;stico temprano" en los ni&#xf1;os con c&#xe1;ncer para mejorar el pron&#xf3;stico: concepto con poco sustento cient&#xed;fico.</ArticleTitle><Pagination><StartPage>520</StartPage><EndPage>526</EndPage><MedlinePgn>520-526</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.18004004</ELocationID><Abstract><AbstractText>La mortalidad por c&#xe1;ncer en ni&#xf1;os mexicanos no ha disminuido a los niveles informados en pa&#xed;ses desarrollados. Una explicaci&#xf3;n frecuentemente declarada es el alto porcentaje (57.3 %) de pacientes diagnosticados en estadios avanzados (III/IV), atribuible a errores en la sospecha o en la metodolog&#xed;a empleada, consideraci&#xf3;n dudosa si se toma en cuenta que el tiempo de diagn&#xf3;stico y la proporci&#xf3;n de estadios avanzados en M&#xe9;xico son semejantes a los de pa&#xed;ses desarrollados. En la mayor&#xed;a de los ni&#xf1;os con c&#xe1;ncer, los d&#xed;as transcurridos desde el primer s&#xed;ntoma a momento del diagn&#xf3;stico oncol&#xf3;gico no correlacionan con el estadio cl&#xed;nico y tampoco con la probabilidad de supervivencia. El &#xe9;xito en la supervivencia depende en gran medida del tratamiento integral (espec&#xed;fico y de la atenci&#xf3;n a las complicaciones). Esta visi&#xf3;n obliga a estrategias dirigidas principalmente a invertir m&#xe1;s recursos en opciones terap&#xe9;uticas eficaces y eficientes, capacitaci&#xf3;n oncol&#xf3;gica integral del equipo de salud (m&#xe9;dicos, enfermeras, t&#xe9;cnicos), tecnolog&#xed;as diagn&#xf3;sticas, fomento a la colaboraci&#xf3;n interinstitucional e internacional y apoyo socioecon&#xf3;mico a las familias durante el proceso terap&#xe9;utico. Cancer mortality in Mexican children has not decreased to the levels reported in developed countries. A commonly proposed explanation is the high percentage (53.7%) of patients diagnosed at advanced stages (III/IV), which is attributed to erroneous assumptions or mistakes in the diagnostic approach &#x2013;a questionable consideration taking into account that both time to diagnosis and the proportion of advanced stage cases in Mexico are similar to those in developed countries. In most cancer cases in children, the number of days elapsed from the moment of the first symptom to the cancer diagnosis is not correlated with clinical stage, and neither with the probability of survival. Survival success largely depends on comprehensive treatment (specific and for the care of complications). This view calls for strategies mainly aimed at spending more resources on efficacious and efficient therapeutic strategies, comprehensive oncology training of healthcare personnel (physicians, nurses and technicians), diagnostic technologies, promotion of interinstitutional and international collaboration and socioeconomic support to families during the therapeutic process.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2018 Secretar&#xcd;a de Salud.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fajardo-Guti&#xe9;rrez</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Pediatr&#xed;a, Unidad de Investigaci&#xf3;n en Epidemiolog&#xed;a Cl&#xed;nica, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rend&#xf3;n-Mac&#xed;as</LastName><ForeName>Mario Enrique</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Pediatr&#xed;a, Unidad de Investigaci&#xf3;n en Epidemiolog&#xed;a Cl&#xed;nica, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="Y">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="Y">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013534" MajorTopicYN="N">Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer in children</Keyword><Keyword MajorTopicYN="N">Cancer stage</Keyword><Keyword MajorTopicYN="N">Cancer survival</Keyword><Keyword MajorTopicYN="N">C&#xe1;ncer en ni&#xf1;os</Keyword><Keyword MajorTopicYN="N">Estadio oncol&#xf3;gico</Keyword><Keyword MajorTopicYN="N">Supervivencia oncol&#xf3;gica</Keyword><Keyword MajorTopicYN="N">Tiempo de diagn&#xf3;stico</Keyword><Keyword MajorTopicYN="N">Time to diagnosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30250314</ArticleId><ArticleId IdType="doi">10.24875/GMM.18004004</ArticleId><ArticleId IdType="pii">j154/4/520</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23684446</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1968</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurologia (Barcelona, Spain)</Title><ISOAbbreviation>Neurologia</ISOAbbreviation></Journal><ArticleTitle>From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>93</EndPage><MedlinePgn>86-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nrl.2013.02.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0213-4853(13)00057-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Rivastigmine, a treatment for mild to moderate Alzheimer disease (AD), is the first cholinesterase inhibitor to be available in the transdermal format. We aim to describe user experience and satisfaction with the rivastigmine patch, as well as any clinical changes perceived in patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Observational, cross-sectional, multicentre study with 239 investigators and 1851 informal caregivers of patients with mild to moderate AD. Patients were treated with transdermal rivastigmine patches for&#xa0;&#x2265;&#xa0;6 months and had previously received high doses of oral rivastigmine.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean caregiver age was 59.8&#xb1;14.4 years and 70.9% were women. They spent 10.0&#xb1;7.1hours per day providing care and 79.8% lived with the patient. Patch instructions were described as easy to follow by 97.1% of the caregivers and 92.1% of them rated patch application as easy or very easy. The most commonly cited disadvantage was adhesion problems (26.8%). Discontinuation of treatment was due to cutaneous reactions in most cases. Overall, 76.5% of the caregivers were satisfied or very satisfied with transdermal treatment and 77.4% considered that its interference with daily activities was minimal or null. The patch was preferred to oral treatment by 94.3% of caregivers. Clinical Global Impression of Change ratings improved according to 61.3% of the caregivers and 53% of the investigators. Few caregivers reported medication forgetfulness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most caregivers of patients with mild to moderate AD preferred the transdermal format of rivastigmine to the oral format. Caregivers also reported overall satisfaction, ease of use, and reduced impact on daily activities for transdermal rivastigmine format, in addition to patient improvement compared to their condition under the previous treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Sociedad Espa&#xf1;ola de Neurolog&#xed;a. Published by Elsevier Espana. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Re&#xf1;&#xe9;</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidad de Diagn&#xf3;stico y Tratamiento de las Demencias, Servicio de Neurolog&#xed;a, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Espa&#xf1;a. Electronic address: udtd@bellvitgehospital.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricart</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento M&#xe9;dico, Novartis Farmac&#xe9;utica, S.A., Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento M&#xe9;dico, Novartis Farmac&#xe9;utica, S.A., Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>researchers in the Experience study</CollectiveName></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Neurologia</MedlineTA><NlmUniqueID>9005460</NlmUniqueID><ISSNLinking>0213-4853</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057968" MajorTopicYN="N">Transdermal Patch</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">Clinical Global Impression of Change</Keyword><Keyword MajorTopicYN="N">Cuidador informal</Keyword><Keyword MajorTopicYN="N">Cumplimiento terap&#xe9;utico</Keyword><Keyword MajorTopicYN="N">Enfermedad de Alzheimer</Keyword><Keyword MajorTopicYN="N">Impresi&#xf3;n Cl&#xed;nica Global de Cambio</Keyword><Keyword MajorTopicYN="N">Informal caregiver</Keyword><Keyword MajorTopicYN="N">Parche transd&#xe9;rmico</Keyword><Keyword MajorTopicYN="N">Rivastigmina</Keyword><Keyword MajorTopicYN="N">Rivastigmine</Keyword><Keyword MajorTopicYN="N">Satisfacci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Satisfaction</Keyword><Keyword MajorTopicYN="N">Transdermal patch</Keyword><Keyword MajorTopicYN="N">Treatment compliance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23684446</ArticleId><ArticleId IdType="doi">10.1016/j.nrl.2013.02.012</ArticleId><ArticleId IdType="pii">S0213-4853(13)00057-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>